Skip to main content

Advertisement

Table 1 Demographics and estimates of kidney function in the CRISP population at baseline

From: Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort

Characteristic Total N = 239 Caffeine Consumer N = 188 (79) Non-Caffeine Consumer N = 51 (21) P-value for difference between caffeine and non-caffeine consumers
Age*, years Mean (± sd) 32.3 ± 8.7 32.3 ± 8.9 32.4 ± 9.0 0.935
Median (IQR) 33.8 (25.1, 39.7) 33.6 (25.0, 39.7) 34.2 (16.0, 39.4)
Race (White), n (%) 207 (87) 167 (89) 40 (78) 0.089
Sex (Male), n (%) 96 (40) 78 (41) 18 (35) 0.523
BMI*, kg/m2 Mean (± sd) 25.91 ± 5.3 26.1 ± 5.5 25.3 ± 4.3 0.564
Median (IQR) 25.17 (21.98, 28.64) 25.24 (22.04, 29.03) 25.07 (22.06, 27.64)
Smoking, n (%) 40 (17) 36 (19) 4 (8) 0.088
Hypertension, n (%) 146 (61) 113 (60) 33 (65) 0.663
Genotype, n (%)
PKD1 + truncation 127 (53) 100 (53) 27 (53)  
PKD1 + no truncation 60 (25) 49 (26) 11 (22) 0.691
PKD2 + NMD 52 (22) 39 (21) 13 (25)  
htTKV*, ml/m Mean (± sd) 621.6 ± 373.9 606.6 ± 367.7 683.7 ± 403.5 0.222
Median (IQR) 504.4 (350.2, 773.9) 479.9 (342.4, 726.9) 567.5 (382.6, 872.7)
Iothalamate Clearance*ϕ, ml/min/1.73m2 Mean (± sd) 97.7 ± 24.8 98.2 ± 24.6 96.9 ± 25.2 0.358
Median (IQR) 94.70 (78.78, 114.75) 96.36 (78.74, 114.72) 88.71 (79.05, 114.83)
  1. Values are given for the total population and based on caffeine intake. *P-value based on Wilcoxon rank sum test due to violation of t-test assumptions. ϕN = 234 (5 values missing at baseline but contributed subsequent measures for mixed model results). NMD refers to no mutation detected in the genetic analysis